| Abstrakt: |
In general, the majority of common colds occurring in September, October and November are caused by rhinovirus infection, whereas the majority of common cold occurring in January, February and March are caused by Coronavirus infections. Keywords: Antidotes; Antimicrobials; Chalcogens; Common Cold; Coronavirus; Drugs and Therapies; Fluoresceins; Health and Medicine; Methylene Blue; Methylene Blue Therapy; Patent Application; Pharmaceuticals; Phenothiazines; Picornaviridae Infections; RNA Viruses; Reactive Oxygen Species; Rhinovirus; Risk and Prevention; Rose Bengal; Singlet Oxygen; Urinary Antiinfectives; Viral; Virology EN Antidotes Antimicrobials Chalcogens Common Cold Coronavirus Drugs and Therapies Fluoresceins Health and Medicine Methylene Blue Methylene Blue Therapy Patent Application Pharmaceuticals Phenothiazines Picornaviridae Infections RNA Viruses Reactive Oxygen Species Rhinovirus Risk and Prevention Rose Bengal Singlet Oxygen Urinary Antiinfectives Viral Virology 1584 1584 1 04/10/23 20230414 NES 230414 2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors Floyd, William Clary (Chester, SC, US); Kozikowski, Alan P. (Wallace, WI, US); Stubbs, Peter (York, GB), filed on November 4, 2022, was made available online on March 23, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. In the prior art no fast working and efficient composition has been provided for preventing and/or treating common colds initiated by viral infections caused by the cold viruses, such as rhino virus, corona virus, adenovirus, coxsackie virus, RS-virus, echovirus or other cold viruses yielding the usual well known cold syndromes in patients. [Extracted from the article] |
